BioInItaly Newsletter

La vetrina del biotech italiano all’estero

BioInItaly nr. 10 - 2012

03 dic, 2012

Eporgen’s portfolio company Genovax sells GX301, its clinical-stage therapeutic vaccine for the treatment of various types of cancer, to Mediolanum Farmaceutici

Mediolanum Farmaceutici SpA, a privately owned company that leads the Mediolanum Farmaceutici Group of companies, and Genovax srl, a private company which belongs to the portfolio of Eporgen Venture and was originated from the University of Genoa, announced the acquisition by Mediolanum of the global rights to GX301, Genovax’s therapeutic vaccine to treat various types of cancer. The first clinical study with GX301 was successfully completed earlier this year in prostate and renal cancer patients. Further clinical studies are scheduled to be initiated in the next few months, and all future development and commercialization activities will be the responsibility of Mediolanum with the support of Genovax. Under the agreement, Genovax will receive upfront and milestone payments as well as royalties.
Genovax was founded in March 2008 in Ivrea by Prof. Francesco Indiveri, Prof. Gilberto Filaci, Dr Daniela Fenoglio, Dr Giuseppe Balbi and Dr Domenico Criscuolo, with the financial support of Eporgen Venture. The science behind Genovax’s technology was originated at the Centre of Excellence for Biomedical Research (CEBR), which is based at the University of Genoa.

TOP srl announces a collaboration with Charles River Laboratories International for the marketing and sales in North America (USA and Canada) of its products.

TOP (Transgenic Operative Products) S.r.l. announced that it has signed an agreement to promote and market 3 of its products in North America (U.S. and Canada) with Charles River Laboratories International, Inc., a world leader provider of models for biological research and pharmaceutical industry.
Under this agreement, Charles River has become the exclusive supplier for North America of three TOP S.r.l. products, licensed products will maintain their original brand (repTOP™). This agreement will allow access to TOP S.r.l. to the North American biotechnology market through the Charles River extensive sales network.
TOP S.r.l. mouse models marketed in North America by Charles River are the following:
• repTOP™mitoIRE for researching proliferative effects in oncology, regenerative medicine and toxicology.
• repTOP™ERE-Luc for assessing stimulation and activity of the estrogen receptors, with primary area of research in reproductive functions and dysfunctions, menopause and related diseases, and hormone regulated neurological disorders (depression and neurodegeneration)
• repTOP™PPRE-Luc for the study of peroxisome proliferation in diabetes, arteriosclerosis, inflammation, lipid metabolism disorders and cardiovascular disease

TOP (Transgenic Operative Products) S.r.l.,, is a research biotech Company originated from the University of Milan, Italy, backed by an important Italian Venture Capital Firm (NEXT fund managed by Finlombarda Gestioni SGR) and collaborating with major pharmaceutical and biotechnology organizations. TOP is located at the Parco Tecnologico Padano in Lodi, near Milan (Italy).  
Using superior technology developed at the University of Milan in the laboratories of the University of Milan, luciferase genes (the reporter) have been engineered to be under the control of three different promoters which allow the in vivo imaging of physiological and pathological processes using a non-invasive technique. Coupled with a low signal to noise ratio, good reproducibility and high specificity, these models offer a versatile way to quantitatively assess both endogenous processes, such as estrogen receptor activity during the estrous cycle (repTOP™ERE-Luc), toxicological/pathological end points such as tumor development over time (repTOP™mitoIRE) or studying the role of Peroxisome Proliferator Activated Receptors(PPARs) in Amytrophic Lateral Sclerosis by crossing with hSOD1G93A mice (repTOP™PPRE-Luc).
More than 40 publications in leading scientific journals (e.g. Nature Reviews Drug Discovery, Nature Medicine, PNAS, TIPS) already use the repTOP™ reporter mice technology.